Industry
Urigen
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
Failure Rate
66.7%
2 terminated/withdrawn out of 3 trials
Success Rate
33.3%
-53.2% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed trials have results
Key Signals
2 with results
Enrollment Performance
Analytics
Phase 2
3(100.0%)
3Total
Phase 2(3)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT02591199Phase 2Terminated
Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Role: lead
NCT00517868Phase 2Terminated
Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis
Role: lead
NCT00256542Phase 2Completed
Study of U101 for Bladder Pain and/or Urgency
Role: lead
All 3 trials loaded